Back

Impact of Geographic and Person-Centered Barriers on Clinical Outcomes of Latino Patients With Multiple Sclerosis and Related Disorders

Finkelstein, L.; Rosario, P.; Martinez, A.; Dujmovic Basuroski, I.; Saylor, D.; Diaz, M. M.

2026-06-02 neurology
10.64898/2026.05.29.26354488 medRxiv
Show abstract

Background Social and geographic barriers contribute to worse outcomes in patients with multiple sclerosis (MS) and related disorders, but these factors remain poorly characterized among Latino patients. We evaluated associations between distance to specialty care, neighborhood deprivation, insurance status, and clinical outcomes among Latinos with MS and related disorders. Methods We conducted a retrospective study of Latino adults with MS, neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody-associated disease. Demographic, clinical, and socioeconomic variables were abstracted from the medical record. Distance to care was defined as residence [&ge;]50 vs. <50 miles from clinic and neighborhood deprivation as Area Deprivation Index (ADI) state rank. We used unadjusted and multivariable regression to evaluate associations with Expanded Disability Status Scale (EDSS) score, annualized relapse rate (ARR), and disease-modifying therapy (DMT) non-adherence. Results Among 99 Latino patients, 84 had MS, 11 MOGAD, and 4 NMOSD; 46.5% lived [&ge;]50 miles from clinic. Living [&ge;]50 miles from clinic was associated with higher EDSS scores in unadjusted analyses, but not after covariate adjustment. In multivariable analyses, Medicaid insurance was associated with higher EDSS compared with commercial insurance ({beta}=1.071, p=0.031) and higher ARR ({beta}=0.230, p=0.022). Higher ADI showed a non-significant trend toward higher EDSS ({beta}=0.147 per 1-decile increase, p=0.068). DMT non-adherence was not significantly associated with covariates. Conclusions In this cohort of Latinos with CNS demyelinating diseases, Medicaid insurance was associated with greater disability level and higher relapse activity. These findings suggest that insurance status should be considered when designing strategies to improve access to neuroimmunology care.

Matching journals

The top 2 journals account for 50% of the predicted probability mass.

1
Multiple Sclerosis and Related Disorders
15 papers in training set
Top 0.1%
33.2%
2
Multiple Sclerosis Journal
18 papers in training set
Top 0.1%
18.7%
50% of probability mass above
3
Frontiers in Neurology
91 papers in training set
Top 0.5%
10.2%
4
Neurology Neuroimmunology & Neuroinflammation
11 papers in training set
Top 0.1%
4.9%
5
Neurology
44 papers in training set
Top 0.3%
4.3%
6
PLOS ONE
4510 papers in training set
Top 38%
3.6%
7
Annals of Clinical and Translational Neurology
29 papers in training set
Top 0.3%
3.1%
8
Journal of the Neurological Sciences
17 papers in training set
Top 0.2%
1.9%
9
Journal of Neurology, Neurosurgery & Psychiatry
29 papers in training set
Top 0.6%
1.8%
10
European Journal of Neurology
20 papers in training set
Top 0.4%
1.2%
11
Journal of Neuroinflammation
50 papers in training set
Top 0.7%
1.0%
12
Brain, Behavior, and Immunity
105 papers in training set
Top 2%
0.9%
13
Journal of Neurology
26 papers in training set
Top 1%
0.9%
14
Annals of Neurology
57 papers in training set
Top 2%
0.8%
15
Brain
154 papers in training set
Top 5%
0.8%
16
PLOS Biology
408 papers in training set
Top 19%
0.8%
17
Scientific Reports
3102 papers in training set
Top 74%
0.8%
18
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 45%
0.8%
19
Journal of Advanced Research
15 papers in training set
Top 0.8%
0.8%
20
Trials
25 papers in training set
Top 2%
0.8%
21
Journal of Clinical Medicine
91 papers in training set
Top 7%
0.6%